--- title: "12 Health Care Stocks Moving In Thursday's Pre-Market Session" type: "News" locale: "en" url: "https://longbridge.com/en/news/290197223.md" description: "In Thursday's pre-market session, several healthcare stocks saw significant movement. Aditxt surged 247.7% to $0.02, while CervoMed rose 25.72% to $4.79. Other gainers included QTREX Quantum, Butterfly Network, Spero Therapeutics, and Agape ATP. Conversely, Profusa dropped 31.0% to $0.18, NewGenIvf fell 22.33% to $0.62, and Elicio Therapeutics declined 20.73% to $3.73. Losers also included Ernexa Therapeutics, NovoCure, and Lunai Bioworks." datetime: "2026-06-18T12:06:41.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/290197223.md) - [en](https://longbridge.com/en/news/290197223.md) - [zh-HK](https://longbridge.com/zh-HK/news/290197223.md) --- # 12 Health Care Stocks Moving In Thursday's Pre-Market Session ### Gainers - **Aditxt** (NASDAQ:ADTX) stock moved upwards by 247.7% to $0.02 during Thursday's pre-market session. - **CervoMed** (NASDAQ:CRVO) shares increased by 25.72% to $4.79. The market value of their outstanding shares is at $35.2 million. - **QTREX Quantum** (NASDAQ:QTEX) stock rose 22.63% to $2.33. The market value of their outstanding shares is at $99.9 million. - **Butterfly Network** (NYSE:BFLY) stock increased by 16.85% to $6.67. The market value of their outstanding shares is at $1.4 billion. - **Spero Therapeutics** (NASDAQ:SPRO) shares rose 16.11% to $2.45. The market value of their outstanding shares is at $122.1 million. - **Agape ATP** (NASDAQ:ATPC) shares rose 15.75% to $3.16. The market value of their outstanding shares is at $2.7 million. ### Losers - **Profusa** (NASDAQ:PFSA) shares declined by 31.0% to $0.18 during Thursday's pre-market session. The company's market cap stands at $1.1 million. - **NewGenIvf Group** (NASDAQ:NIVF) stock decreased by 22.33% to $0.62. The market value of their outstanding shares is at $2.2 million. - **Elicio Therapeutics** (NASDAQ:ELTX) shares fell 20.73% to $3.73. The market value of their outstanding shares is at $89.8 million. - **Ernexa Therapeutics** (NASDAQ:ERNA) shares declined by 14.95% to $5.01. The market value of their outstanding shares is at $6.8 million. - **NovoCure** (NASDAQ:NVCR) stock fell 14.57% to $15.25. The company's market cap stands at $2.0 billion. - **Lunai Bioworks** (NASDAQ:LNAI) stock fell 14.1% to $3.44. The market value of their outstanding shares is at $18.1 million. **See Also:** www.benzinga.com/money/best-healthcare-stocks/ This article was generated by Benzinga's automated content engine and reviewed by an editor. ### Related Stocks - [LNAI.US](https://longbridge.com/en/quote/LNAI.US.md) - [NVCR.US](https://longbridge.com/en/quote/NVCR.US.md) - [SPRO.US](https://longbridge.com/en/quote/SPRO.US.md) - [PFSA.US](https://longbridge.com/en/quote/PFSA.US.md) - [ATPC.US](https://longbridge.com/en/quote/ATPC.US.md) - [NIVF.US](https://longbridge.com/en/quote/NIVF.US.md) - [CRVO.US](https://longbridge.com/en/quote/CRVO.US.md) - [ERNA.US](https://longbridge.com/en/quote/ERNA.US.md) - [ADTX.US](https://longbridge.com/en/quote/ADTX.US.md) - [QTEX.US](https://longbridge.com/en/quote/QTEX.US.md) - [ELTX.US](https://longbridge.com/en/quote/ELTX.US.md) - [BFLY.US](https://longbridge.com/en/quote/BFLY.US.md) - [BFLY+.US](https://longbridge.com/en/quote/BFLY+.US.md) - [BFLYW.US](https://longbridge.com/en/quote/BFLYW.US.md) - [NVACW.US](https://longbridge.com/en/quote/NVACW.US.md) - [NIVFW.US](https://longbridge.com/en/quote/NIVFW.US.md) - [RENB.US](https://longbridge.com/en/quote/RENB.US.md) ## Related News & Research - [Cervo posts investor presentation on website covering clinical, development and financial updates](https://longbridge.com/en/news/289829022.md) - [Butterfly Network Climbs On Midjourney Hype Despite FDA, Reimbursement Questions](https://longbridge.com/en/news/290230361.md) - [Novocure says Phase 3 TRIDENT glioblastoma trial misses overall survival endpoint for earlier TTFields use](https://longbridge.com/en/news/290185824.md) - [QTREX Quantum stock rallies as its AME system enters commercial production](https://longbridge.com/en/news/289795534.md) - [NovoCure Reports Phase 3 TRIDENT Trial Topline Results](https://longbridge.com/en/news/290192961.md)